Regeneron Q3 2026 slides: record results, $8B Sanofi alliance

Regeneron reported Q3 2026 revenue of $5.1B, up 36% year over year, and non-GAAP EPS of $20.07, up 70%, beating expectations; shares rose 13.33% to $927.89. The expanded Sanofi alliance could provide up to $8B in consideration, including $1B upfront, while retaining a 50:50 profit split on new products. The company also reported strong growth across key medicines and outlined multiple clinical and regulatory catalysts, alongside plans for 2027 R&D spending to increase by a mid-teens percentage from 2026.

Analysis

The key underwriting question is earnings quality, not pipeline breadth. The alliance’s upfront payment can support near-term reported results, but contingent milestones should not be valued like recurring profit share; separately, a mid-teens R&D increase in 2027 may absorb part of commercial growth before later-stage assets contribute. This creates a risk that a strong headline EPS run-rate overstates the pace of durable per-share growth.

Verify the source figures against Regeneron’s filing before modeling: the article mixes company revenue, collaboration revenue, and global product sales, which are different scopes and cannot be compared directly. In particular, global Dupixent sales are not equivalent to Regeneron-recognized revenue. This matters for estimating how much of the reported upside is recurring and attributable to REGN.

Over 1–3 months, cemdisiran’s FDA decision and PNH data are asymmetric catalysts; a favorable result could validate platform breadth, while safety, efficacy, or labeling limitations would weaken the pipeline-premium case. Over 6–18 months, the bigger test is whether new programs convert into durable launches against established competitors, including Roche in retinal disease and Eli Lilly and Novo Nordisk in obesity. EYLEA HD uptake is positive only if it protects franchise economics as the older product is displaced.

After the sharp rerating, consensus may be extrapolating current growth while underweighting one-time alliance revenue, rising R&D, and clinical execution risk. No valuation or independently verified consensus data are supplied, so avoid a price target or assuming further multiple expansion.

Key Decisions for Investors

• Do not chase the post-results gap with an unhedged new position. For investors seeking exposure, consider staged REGN entry on a retracement that holds after the next verified earnings disclosure; the thesis is durable product growth, not the one-time upfront payment.
• For a catalyst-driven position, keep sizing modest into the November cemdisiran decision and Q4 PNH readout. Reassess promptly on the actual label, efficacy, and safety data; a restrictive label or disappointing PNH result falsifies the near-term pipeline-validation thesis.
• Model alliance milestones separately from recurring collaboration economics, and confirm the product-sales/revenue scopes in the company filing. If recurring profit contribution is materially below what the presentation’s headline figures imply, reduce forward earnings assumptions rather than extrapolating the reported growth rate.
• Monitor EYLEA HD franchise sales and physician demand alongside Roche’s competitive progress, and track 2027 R&D spending against launch and trial milestones. Slowing franchise demand or spending rising without timely clinical progress would argue for reducing exposure.